|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00805064 |
|
Date of registration:
|
04/12/2008 |
|
Primary sponsor: |
|
|
Public title:
|
Combined Triple Procedure in Retinal Vein Occlusion (RVO)
|
|
Scientific title:
|
Intravitreal Combination Therapy Using Triamcinolone and Bevacizumab Improves Vision in Patients With Retinal Vein Occlusion |
|
Date of first enrolment:
|
January 2006 |
|
Target sample size:
|
40 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00805064 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Contacts
|
|
Name:
|
Michael Koss, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Department of VitreoRetinal Surgery ZAU JWGU |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Ischemic central RVO (CRVO)
- Non-ischemic CRVO
- Branch RVO (BRVO)
Exclusion Criteria:
- Visual deterioration due to acute or chronic inflammation
- Post trauma
- Macular edema of other origin
- Intravitreal drug treatment within last 4 months
Age minimum:
21 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Retinal Vein Occlusion
|
|
Intervention(s)
|
|
Drug: triamcinolone and bevacizumab
|
|
Primary Outcome(s)
|
|
BCVA
[Time Frame: day of exam]
|
|
Secondary ID(s)
|
|
MK-KTRVO-2008
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|